An investor in NASDAQ:ALXN shares filed a lawsuit against Alexion Pharmaceuticals, Inc over alleged violations of Federal Securities Laws.
Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 17, 2017. NASDAQ:ALXN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff claims that the defendants issued materially false and misleading statements to investors and/or failed to disclose that Alexion Pharmaceuticals, Inc employed improper sales practices with respect to Soliris, that consequently, Alexion’s revenues from Soliris sales were unlikely to be sustainable, and that as a result, Alexion’s public statements were materially false and misleading at all relevant times.
On June 6, 2016, Alexion Pharmaceuticals, Inc announced topline results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis.
On November 9, 2016, Alexion Pharmaceuticals, Inc announced that the Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company’s sales practices of Soliris. Alexion Pharmaceuticals, Inc said that the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices and that the Audit and Finance Committee has retained outside counsel to assist it in the investigation. Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) declined on November 11, 2016 to $111.66 per share.
Those who purchased NASDAQ:ALXN shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com